CN101077380A - 一种抗病毒的药物组合物及其制备方法 - Google Patents
一种抗病毒的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN101077380A CN101077380A CN 200610081518 CN200610081518A CN101077380A CN 101077380 A CN101077380 A CN 101077380A CN 200610081518 CN200610081518 CN 200610081518 CN 200610081518 A CN200610081518 A CN 200610081518A CN 101077380 A CN101077380 A CN 101077380A
- Authority
- CN
- China
- Prior art keywords
- powder
- weight portions
- add
- radix
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 230000002155 anti-virotic effect Effects 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 102
- 239000003814 drug Substances 0.000 claims abstract description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000001291 vacuum drying Methods 0.000 claims abstract description 20
- 238000009835 boiling Methods 0.000 claims abstract description 10
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 229940079593 drug Drugs 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000006071 cream Substances 0.000 claims description 27
- 241000196133 Dryopteris Species 0.000 claims description 23
- 241000628997 Flos Species 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000007796 conventional method Methods 0.000 claims description 9
- 230000006837 decompression Effects 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 6
- 239000000890 drug combination Substances 0.000 claims description 3
- XGFJCRNRWOXGQM-UHFFFAOYSA-N hot-2 Chemical compound CCSC1=CC(OC)=C(CCNO)C=C1OC XGFJCRNRWOXGQM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 24
- 241000894006 Bacteria Species 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 241000050051 Chelone glabra Species 0.000 abstract 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 241000431991 Aglaomorpha quercifolia Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 48
- 239000003795 chemical substances by application Substances 0.000 description 46
- 210000002966 serum Anatomy 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 30
- 239000007788 liquid Substances 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 20
- 230000037396 body weight Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 235000010603 pastilles Nutrition 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 206010022000 influenza Diseases 0.000 description 13
- 230000036760 body temperature Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000711573 Coronaviridae Species 0.000 description 11
- 239000008176 lyophilized powder Substances 0.000 description 11
- 231100001274 therapeutic index Toxicity 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000029052 metamorphosis Effects 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 108010006464 Hemolysin Proteins Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 239000003228 hemolysin Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 210000000436 anus Anatomy 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000012109 statistical procedure Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 231100000645 Reed–Muench method Toxicity 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 231100000028 nontoxic concentration Toxicity 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940100050 virazole Drugs 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 208000031636 Body Temperature Changes Diseases 0.000 description 3
- 241000167880 Hirundinidae Species 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001698 pyrogenic effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241001478240 Coccus Species 0.000 description 2
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 231100001134 median toxic concentration Toxicity 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
含药血清冻干粉 | |
TC0(mg/ml)TC50(mg/ml) | 0.75±01.5±0 |
药物 | IC50(mg/ml) | MIC(mg/ml) | TI |
血清冻干粉更昔洛韦 | 0.0470.0112 | 0.0941.5 | 8256 |
含药血清冻干粉 | 原药液 | |
TC0(mg/ml)TC50(mg/ml) | 0.3130.396 | 0.6251.125 |
病毒株 | 病毒对照 | 含药血清(mg/ml) | 原药液(mg/ml) | ||||||
0.313 | 0.156 | 0.078 | 0.039 | 0.625 | 0.313 | 0.156 | 0.078 | ||
副流感RSVH1H2A3A7CoxB5CoxB6 | 44444444444434433333333344444444 | -**-**-**-**-**-**44444444 | -**1111**-**-**1111**1111**44444444 | 1111**3333**1122**1122**1121**2111**44444444 | 2222**44441222**1222**2222**2222**44444444 | -**-**-**-**-**-**44444444 | 1111**1111**1111**1111**1111**1111**44444444 | 2222**2333**2222**2222**2222**2222**44444444 | 2222**44442222**2222**3221**3221**44444444 |
药物病毒 | 含药血清 | 原药液 | ||||
TC50(mg/ml) | IC50(mg/ml) | TI | TC50(mg/ml) | IC50(mg/ml) | TI | |
副流感RSVH1H2A3A7CoxB5CoxB6 | 0.3960.3960.3960.3960.3960.396-- | 0.0560.110.0790.0790.0620.062-- | 7.13.65.15.16.396.39-- | 1.1251.1251.1251.1251.1251.125-- | 0.2240.2240.2240.2240.2060.206-- | 5.225.225.225.225.465.46-- |
组别 | 给药量(生药g/kg/d) | 动物数 | 肺指数( X±S) | 抑制率 |
正常组模型组病毒唑双黄连大剂量中剂量小剂量 | --0.075.6115.52.75 | 10101010101010 | 0.88±0.101.77±0.25##1.08±0.09**1.49±0.28*1.32±0.30**1.50±0.30*1.37±0.43* | 27.3615.7325.3415.4322.63 |
组别 | 给药量(生药g/kg/d) | 动物数 | 死亡率(%) | 保护率(%) | 平均生存天数( X±S) | 生命延长率(%) |
模型组病毒唑大剂量中剂量小剂量 | -0.07115.52.75 | 2020202020 | 955807575 | 94.74**15.7921.0521.05 | 7.8±1.85#12.75±1.12**9.25±2.22*9.25±2.40*8.60±2.70 | 63.4618.5918.5910.26 |
药物浓度 | 细菌对照 | 青霉素组 | 含药血清组(mg/ml) | 原药液组(mg/ml) | ||||
12.5 | 6.3 | 3.2 | 50 | 25 | 12.5 | |||
金葡球菌白葡球菌大肠杆菌乙链球菌肺炎杆菌卡他菌绿脓杆菌变形杆菌 | ++++++++ | ----+--- | -+++++-- | -+++++++ | ++++++++ | --+-+--- | -+++++-- | +++++++- |
组别 | 给药量(g/kg/d) | CD4 | CD8 | CD4/CD8 |
正常组模型组双黄连大剂量中剂量小剂量 | --0.88115.52.75 | 45.45±7.7064.78±5.26##**57.56±9.91##53.09±7.14#**62.38±4.36##62.77±8.07## | 11.20±2.8317.24±3.69##**15.30±7.0614.00±4.6218.00±4.6311.81±3.94** | 4.28±1.343.93±0.914.50±2.054.20±1.544.34±2.085.82±1.90** |
组别 | 给药量(生药g/kg/d) | 动物数 | 溶血素IgM |
正常组模型组左旋咪唑小剂量组中剂量组大剂量组 | --0.07115.52.75 | 10101010810 | 29.92±11.1316.16±9.02##28.71±9.41**29.42±7.64**31.8±16.43*27.28±18.78 |
组别 | 给药量(生药g/kg/d) | 动物数 | 胸腺指数( X±S) | 脾指数( X±S) |
正常组模型组左旋咪唑小剂量组中剂量组大剂量组 | --0.0711552.75 | 10101010810 | 3.12±0.32.16±0.5△△△2.59±0.4*2.45±0.42.67±0.5*2.73±0.6* | 3.52±0.42.68±0.4△△△3.15±0.3*2.97±0.43.05±0.3*3.25±0.4** |
组别 | 动物数 | 给药量(g/kg/d) | NO( X±S) |
正常组模型组双黄连大剂量中剂量小剂量 | -9810109 | --0.07115.52.65 | 49.403±12.19349.403±12.19335.461±10.080#**38.822±9.355#*48.668±12.410 |
组别 | 剂量g/kg/d | 动物数 | 肉芽干肿(mg) |
对照组双黄连大剂量中剂量小剂量 | -8.8631.5 | 1111111111 | 40.60±8.3037.68±6.2537.47±10.8638.36±10.1540.60±8.30 |
组别 | 剂量g/kg/d | 动物数 | 脏器指数(g/100g体重) | |
脾脏 | 胸腺 | |||
对照组双黄连大剂量中剂量小剂量 | -0.88631.5 | 1111111111 | 0.30±0.030.29±0.030.30±0.060.31±0.050.30±0.01 | 0.20±0.020.19±0.030.18±0.020.21±0.050.21±0.01 |
组别 | 剂量g/kg/d | 动物数 | OD值 | 抑制率 |
模型对照组双黄连大剂量中剂量小剂量 | -1.7115.52.75 | 1111111111 | 0.48±0.060.37±0.06**0.27±0.05**0.43±0.070.48±0.06 | 19.5222.5442.6210.06 |
组别 | 基础体温 | 模后体温 | 给药后体温(℃)( X±S) | |||
0.5h | 1h | 15h | 2h | |||
模型组双黄连大剂量中剂量小剂量 | 37.80±0.2437.60±0.2537.50±0.3037.82±0.2537.70±0.21 | 39.00±0.2938.85±0.3238.80±0.4539.10±0.2538.9±0.22 | 39.00±0..38(1.18±0.21)38.63±0.32(1.03±0.16)38.50±0.60(1.10±0.40)38.50±0.19(0.68±0.35)**38.50±0.29(0.80±0.30)* | 39.20±0.62(1.62±0.31)38.77±0.36(1.17±0.26)*38.60±0.68(1.12±0.44)*38.70±027(0.83±0.49)**38.60±0.46(0.88±0.44)** | 38.90±0.56(1.15±0.41)38.72±0.31(1.12±0.17)38.60±0.64(1.10±0.40)38.80±0.36(1.02±0.52)38.70±0.54(1.00±0.45) | 38.80±0.55(0.98±0.40)38.57±0.27(0.97±0.16)38.50±0.66(1.10±0.40)38.90±0.23(1.07±0.43)38.70±0.51(0.98±0.43) |
组别 | 剂量mg/kg/d | 动物数 | 扭体数(次) | 抑制率% |
模型对照组阿司匹林双黄连大剂量中剂量小剂量 | -40088027013565 | 121212121212 | 25.08±12.381.75±2.83**15.08±9.64*10.17±7.05**15.33±6.14*17.83±11.78 | 93.0239.8759.4738.8728.9 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100815188A CN100502916C (zh) | 2006-05-25 | 2006-05-25 | 一种抗病毒的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100815188A CN100502916C (zh) | 2006-05-25 | 2006-05-25 | 一种抗病毒的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101077380A true CN101077380A (zh) | 2007-11-28 |
CN100502916C CN100502916C (zh) | 2009-06-24 |
Family
ID=38905151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100815188A Active CN100502916C (zh) | 2006-05-25 | 2006-05-25 | 一种抗病毒的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100502916C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947297A (zh) * | 2010-09-17 | 2011-01-19 | 北京中医药大学东直门医院 | 一种治疗老年肺炎的中药组合物、免煎颗粒剂及其制备方法 |
CN104111295A (zh) * | 2014-07-24 | 2014-10-22 | 神威药业集团有限公司 | 一种中药制剂的质量控制方法 |
CN111632116A (zh) * | 2020-06-17 | 2020-09-08 | 上海凯宝药业股份有限公司 | 一种抗病毒性感冒中药制剂的制备方法 |
CN115089652A (zh) * | 2022-06-14 | 2022-09-23 | 深圳市中医院 | 清肺固本汤的中药方剂及其制备方法 |
-
2006
- 2006-05-25 CN CNB2006100815188A patent/CN100502916C/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947297A (zh) * | 2010-09-17 | 2011-01-19 | 北京中医药大学东直门医院 | 一种治疗老年肺炎的中药组合物、免煎颗粒剂及其制备方法 |
CN104111295A (zh) * | 2014-07-24 | 2014-10-22 | 神威药业集团有限公司 | 一种中药制剂的质量控制方法 |
CN111632116A (zh) * | 2020-06-17 | 2020-09-08 | 上海凯宝药业股份有限公司 | 一种抗病毒性感冒中药制剂的制备方法 |
CN115089652A (zh) * | 2022-06-14 | 2022-09-23 | 深圳市中医院 | 清肺固本汤的中药方剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100502916C (zh) | 2009-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1947754A (zh) | 一种治疗小儿哮喘的药物及其制备方法 | |
CN1772081A (zh) | 一种治疗腹泻病的中药组合物 | |
CN1772079A (zh) | 一种治疗上呼吸道感染的药物及其制备方法 | |
CN1314387C (zh) | 一种治疗小儿咳喘的中药及其制备方法 | |
CN101077380A (zh) | 一种抗病毒的药物组合物及其制备方法 | |
CN1943675A (zh) | 清热化痰、止咳平喘的藏药药物组合物及其制备方法 | |
CN102526568B (zh) | 一种中药复方组合物 | |
CN1857362A (zh) | 金感康药物制剂及其制备方法 | |
CN1772026A (zh) | 一种返魂草提取物,它的提取方法及制剂 | |
CN1323668C (zh) | 一种药物组合物及其制药用途 | |
CN1679689A (zh) | 一种清热解毒的中药制剂及其制备方法 | |
CN1903254A (zh) | 治疗风热感冒的复方药物及其制备方法 | |
CN1745788A (zh) | 一种治疗小儿腹泻的中药制剂及制备方法 | |
CN1168488C (zh) | 治疗热淋的中药制剂 | |
CN1698691A (zh) | 一种治疗肺热(毒)咳嗽的药物及其制备方法 | |
CN100337658C (zh) | 治疗感冒风热症的中药组合物及其制备方法 | |
CN1733194A (zh) | 治疗呼吸系统疾病的组合中药材的提取物及提取方法 | |
CN102861333B (zh) | 一种高活性抗鸡法氏囊病毒、流感病毒复合抗体口服制剂 | |
CN107349376B (zh) | 一种抗鸡球虫益生药物及其制备方法和应用 | |
CN1919270A (zh) | 组合物,其提取物及它们的药物用途 | |
CN1876151A (zh) | 一种治疗感冒的药物组合物及其制备方法和用途 | |
CN1742845A (zh) | 一种治疗呼吸系统疾患的中药组合物及其制备方法 | |
CN1660259A (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN109833366A (zh) | 一种中药组合物在制备改善免疫作用的药物中的应用 | |
CN1220515C (zh) | 一种治疗咽喉疾病的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHINEWAY PHARMACEUTICAL GROUP LIMITED Free format text: FORMER OWNER: CAO HONGXIN Effective date: 20140410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100700 DONGCHENG DISTRICTK, BEIJING TO: 051430 SHIJIAZHUANG, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140410 Address after: Hebei province Luancheng County South 051430 Patentee after: China Shineway Pharmaceutical Group Co., Ltd. Address before: 100700 Beijing city Dongzhimen Nanxiaojie No. 16 Patentee before: Cao Hongxin |